oral semaglutide cardiovascular outcomes soul trial results 2024 2025 nejm Presented at ACC.25: Among participants SOUL (Semaglutide cardiOvascular oUtcomes triaL)

Yet it remains widely misunderstood in part because it doesnt always align with cultural stereotypes of what an eating disorder looks like. Experts say greater awareness is essential, not only to help people recognize the signs in themselves or loved ones, but to shift how we think about eating disorders in general: as complex mental health conditions that dont discriminate by size, gender, or background

The medication's contraindication applies to pregnancy itself (the pregnant person taking the medication), not to the reproductive contributions of a partner

A retrospective study of patients in the NYU Lupus Cohort found that GLP1-RA use was associated with significantly decreased BMI and did not confer a higher risk of flares, though notably the sample size was small13

Protocol for switching from low-dose tirzepatide (2.5 to 5 mg) If you were on tirzepatide 2.5 mg or 5 mg, your switch is the most straightforward

Manufacturers made false, misleading or incomplete representations of safety

The findings from major trials are impressive